Background Phenotyping allergic rhinitis (AR) by IgE sensitivity and presence of comorbidities may help characterize allergic diseases, provide a clinical framework to inform treatment decisions, and improve clinical trial design. MP-AzeFlu (137µg azelastine hydrochloride + 50 µg fluticasone propionate intranasal spray) is a treatment for AR but the effectiveness of MP-AzeFlu on disease severity by AR phenotypes is unknown. This prospective, noninterventional study evaluated the effectiveness of MP AzeFlu (1 spray in each nostril twice daily for 2 weeks) across novel AR phenotypes.
|Publication status||Published - 6 Jun 2020|
|Event||EAACI Digital Congress 2020 - Digital, London, United Kingdom|
Duration: 6 Jun 2020 → 8 Jun 2020
|Conference||EAACI Digital Congress 2020|
|Period||6/06/20 → 8/06/20|